Various RNAi delivery approaches, such as liposomal complexes (lipoplexes), encapsulation in nanoparticles or polymeric complexes (polyplexes) were developed, from which none met the strict criteria for FDA approval, mostly due to low efficacy and high toxicity [8–12]. Polymer therapeutics is the ...